Who
Reshma Rangwala
EVP & Chief Medical Officer
Company insider
Files Form 4 as: EVP & Chief Medical Officer, Karyopharm Therapeutics; Chief Medical Officer, Aravive.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $200K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 28 Sep 2020
- Last trade
- 14 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,876408 at $9.50 | filing |
| 14 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,876408 at $9.50 | filing |
| 13 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —947 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —947 at $0.00 | filing |
| 21 Apr 2026filed 22 Apr 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,014449 at $8.94 | filing |
| 21 Apr 2026filed 22 Apr 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,014449 at $8.94 | filing |
| 2 Mar 2026filed 3 Mar 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K5,066 at $9.41 | filing |
| 2 Mar 2026filed 3 Mar 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K5,066 at $9.41 | filing |
| 31 Jan 2026filed 3 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,415 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,415 at $0.00 | filing |
| 15 Sep 2025filed 16 Sep 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,623408 at $6.43 | filing |
| 12 Sep 2025filed 16 Sep 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —945 at $0.00 | filing |
| 23 Apr 2025filed 24 Apr 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,585419 at $6.17 | filing |
| 4 Mar 2025filed 6 Mar 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K3,587 at $6.29 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,833 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,166 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,416 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,583 at $0.00 | filing |
| 22 Apr 2024filed 23 Apr 2024 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,9436,789 at $1.17 | filing |
| 1 Mar 2024filed 4 Mar 2024 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1635,969 at $1.20 | filing |
News
No headline names them, or the companies they trade most, lately.